医薬品製造受託機関（CMOs）市場トップ50レポート 2022年
Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022
レポート詳細
医薬品製造受託機関（CMOs）市場トップ50レポート 2022年 :本レポートは、新たな収益の柱を目指すリーディングカンパニーが、業界とその背景にあるダイナミクスをより深く理解する上で... もっと見る
※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。
サマリー
レポート詳細
医薬品製造受託機関（CMOs）市場トップ50レポート 2022年:本レポートは、新たな収益の柱を目指すリーディングカンパニーが、業界とその背景にあるダイナミクスをより深く理解する上で、非常に有益なものとなるでしょう。また、異業種への進出や新地域での既存事業の拡大を目指す企業にとっても有用なレポートです。
Visiongainのアナリストによると、製薬業界はビジネスモデルを変えるような大きな変化を遂げつつあります。これは、世界の医薬品受託製造組織の市場参加者にとって、新たな機会の1つを意味します。Visiongainの分析によると、医薬品製造受託機関（CMO）市場は2022年に1,043億9600万米ドルと推定され、2032年までに2,032億4000万米ドルの市場規模に達すると予測されています。
バイオシミラーの需要と受容性の高まりは、製薬会社のCMOにとって大きなチャンスとなり得る。
バイオシミラーの需要の高まりと受容性は、製造受託機関や研究機関にとって大きなチャンスといえます。安価な医療への要求と、革新的な生物学的製剤の今後の特許切れにより、バイオシミラーの大きな機会が提供されます。大手製薬会社やバイオファーマは、バイオシミラーに大きなチャンスがあると見ています。大手の製薬会社やバイオファーマは、バイオシミラーに大きなチャンスがあると見ています。これらの企業は、アウトソーシングプロバイダーとジョイントベンチャーやパートナーシップを形成しています。例えば、2022年3月、ジョンソン・エンド・ジョンソンは、ヤンセン・ファーマスーティカルズ社と南アフリカの製造業者アスペンSAオペレーションズ（Pty）Ltdとの間で、アフリカ大陸全体のCOVID-19接種率を高めることを目的に、初のCOVID-19ワクチンの製造とアフリカに住む人々への提供を可能にする歴史的契約を完了させました。
マーケットリサーチレポートを購入する前に、どのような質問をすべきでしょうか？
- 医薬品製造受託機関（CMOs）市場はどのように進化しているのか？
- 医薬品製造受託機関（CMOs）市場の推進要因と抑制要因は何か？
- 医薬品製造受託機関（CMOs）の各サブマーケット区分は予測期間中にどのように成長し、これらのサブマーケットが2032年に占める売上高はどの程度になるのでしょうか？
- 2022年から2032年にかけて、市場全体の主な牽引役となるのは何か？
- 主要な医薬品製造受託機関（CMOs）市場はマクロ経済のダイナミクスに概ね追随するのか、それとも個々の国市場が他を凌駕するのか？
- 主要プレイヤーは誰で、予測期間中の見通しはどうなのか？
- これらの主要企業の医薬品製造受託機関（CMOs）プロジェクトはどのようなものですか？
- 2022年から2032年にかけて、業界はどのように進化していくのか？現在および今後10年間に実施される医薬品製造受託機関（CMOs）プロジェクトにはどのような意味があるのか？
- 医薬品製造受託機関（CMOs）市場をさらに拡大するために、製品の商業化の必要性は高いか？
- 医薬品製造受託機関（CMOs）市場はどこへ向かい、どのようにすれば市場の最前線に立つことができるのか？
- 新製品やサービスラインに対する最適な投資オプションは何か？
- 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？
このことが、現在、そして今後10年間の医薬品製造受託機関（CMOs）市場にどのような影響を及ぼすかを知る必要があります。
- 370ページにわたる本レポートでは、159の表、212のグラフを独占的に提供します。
- このレポートでは、業界における主要な収益性の高い分野をハイライトしているため、今すぐその分野をターゲットにすることができます。
- 世界規模、地域別の成長分析が含まれています。
- 競合他社が成功した主要なトレンド、変化、収益予測をハイライトしています。
本レポートは、医薬品製造受託機関（CMOs）市場のトップ50が今後10年間にどのように発展し、COVID-19の景気後退と回復の変動に沿うかを今日あなたにお伝えします。この市場は、過去10年間のどの時点よりも今が重要なのです。
2032年までの予測やその他の分析により、商業的な展望が見えてくる
- 2032年までの収益予測に加え、直近の実績、成長率、市場シェアもご覧いただけます。
- ビジネスの展望や展開など、独自の分析もご覧いただけます。
- 定性分析（市場力学、ドライバー、機会、制約、課題など）、PEST分析、ポーターの5つの力分析をご覧いただけます。
本レポートでは、COVID-19が業界と貴社にどのような影響を与えるかについて、データ分析と貴重な洞察を掲載しています。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じています。
世界市場全体およびセグメントの収益予測に加え、5つの地域の収益予測も掲載しています。
- 北米
- 欧州
- アジア太平洋
- 南米
- 中近東・アフリカ
本レポートでは、医薬品製造受託機関（CMOs）市場の上位50社のうち、これらの企業のこのセグメントに焦点を当てた、2022年から2032年までのプロファイルと主要企業の一部を紹介しています。
主要企業と市場成長の可能性
・ Abbott Laboratories
・ AbbVie Inc.
・ Alkermes
・ AstraZeneca
・ Aurobindo Pharma
・ Avid Bioservices, Inc.
・ Bavarian Nordic
・ Baxter Biopharma Solutions
・ Bayer AG
・ BD
・ bioMérieux
・ Boston Scientific Corporation
・ CordenPharma International
・ Catalent Inc.
・ Consort Medical plc
・ CSL Limited
・ Divi’s Laboratories Ltd.
・ Dr. Reddy’s Laboratories Ltd.
・ Dupont
・ Edwards Lifesciences Corporation
・ Eli Lilly and Company
・ Emergent BioSolutions
・ Evonik Industries
・ F. Hoffmann-La Roche Ltd.
・ Fresenius SE＆Co. KGaA
・ Gilead Sciences, Inc.
・ GSK plc
・ Grifols
・ Huapont Life Sciences Co Ltd.
・ INOVIO Pharmaceuticals
・ Johnson ＆ Johnson Services Inc.
・ Koninklijke DSM N.V. (Royal DSM)
・ Lonza
・ McKesson Corporation
・ Merck KGaA
・ Moderna Inc.
・ Nipro Corporation
・ Novartis AG
・ Novavax
・ Novo Nordisk A/S
・ Pfizer Inc.
・ PPD Inc.
・ Sanofi
・ Strides Pharma Science Limited
・ Teva Pharmaceuticals Industries Ltd.
・ Thermo Fisher Scientific Inc.
・ UPM Pharmaceuticals
・ VBI Vaccines Inc.
・ WuXi AppTec
・ ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.
医薬品受託製造機関（CMOs）市場の世界全体の収益、2022年から2032年まで金額ベースで2022年に1,043億9600万米ドルを突破すると弊社は算出しています。また、2032年までの間に売上高が大きく伸びると予測しています。本調査では、最も大きな可能性を秘めた企業を特定しています。彼らの能力、進歩、商業的展望を知ることで、一歩先を行くことができます。
How will the 医薬品製造受託機関（CMOs）市場トップ50レポート 2022年 report help you?
370ページに及ぶ報告書をまとめると、以下のような知見が得られます。
- Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032 Marketの2032年までの収益予測、予測および企業規模、世界および地域レベルでの各予測 - 産業の展望、投資および収益に最も有利な場所を発見してください。
- 5つの地域市場の2032年までの収益予測 - 北米、欧州、アジア太平洋、南米、中東＆アフリカのTop 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032の市場予測をご覧いただけます。
- 既存企業および市場参入を目指す企業の展望 - 医薬品受託製造機関（CMOs）市場の上位50社（2022年～2032年）に関わる主要企業50社の企業プロファイルを掲載しています。
定量的・定性的な分析と独自の予測をご覧いただけます。私たちのレポートだけが持つ情報を入手し、貴重なビジネスインテリジェンスを得ることができます。
他にはない情報
私たちの新しいレポートがあれば、知識の遅れを取り戻し、チャンスを逃す可能性が低くなります。私たちの研究が貴社の調査、分析、意思決定にどのように役立つかをご覧ください。Visiongainの研究は、トップ50の医薬品製造受託機関（CMOs）市場、2022年から2032年、市場をリードする企業のための商業分析を必要とするすべての人のためのものです。データ、トレンド、予測を見つけることができます。
ページTOPに戻る
目次
目次
1.レポートの概要
1.1 調査の目的
1.2 医薬品製造受託機関（CMOs）市場トップ50の紹介
1.3 本レポートが提供するもの
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問には以下が含まれます。
1.6 本レポートは誰のためのものなのか？
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 セカンダリーリサーチ
1.8 よくある質問（FAQ)
1.9 関連するVisiongainのレポート
1.10 Visiongainについて
2 エグゼクティブサマリー
3 市場の概要
3.1 主要な調査結果
3.2 マーケットダイナミクス
3.2.1 市場の推進要因
3.2.1.1 バイオシミラーの普及が進む
3.2.1.2 オーファンドラッグやスペシャリティドラッグへの集中が進む
3.2.1.3 製剤開発サービスに対する需要の高まり
3.2.1.4 バイオ製薬会社は薬物送達技術企業との戦略的協業に努める
3.2.1.5 生産性向上のための継続的な集中力
3.2.1.6 コスト削減の利点が市場成長の原動力
3.2.1.7 新薬開発に伴うリスクを軽減するために
3.2.2 市場の抑制要因
3.2.2.1 製品・プロセス開発への挑戦
3.2.2.2 CMOsの主な課題は、投資する準備ができている企業を誘致すること
3.2.2.3 厳しい規制が市場成長を阻害している
3.2.2.4 製薬会社は特許失効により大きな収益上の課題に直面している
3.2.2.5 高いR&D費用に関する課題
3.2.2.6 ジェネリック医薬品メーカーにおける後方互換性
3.2.3 市場機会
3.2.3.1 製造・包装能力の不足
3.2.3.2 製薬会社は医薬品コストを削減する方法を模索し続けるだろう
3.2.3.3 新しいドラッグデリバリー技術が必要
3.2.3.4 生物学的原薬に焦点を当てた後、化学的原薬が復活するだろう
3.3 COVID-19の影響度分析
3.4 ポーターのファイブフォース分析
3.4.1 供給者パワー
3.4.2 バイヤーパワー
3.4.3 競合他社の競争力
3.4.4 代替品による脅威
3.4.5 新規参入者の脅威
3.5 環境影響度分析
3.5.1 政治的要因
3.5.2 経済
3.5.3 社会
3.5.4 技術的
3.5.5 環境
3.5.6 法律
4 医薬品製造受託機関(CMOs)市場分析：地域別
4.1 主要な調査結果
4.2 地域別市場規模の推定と予測
5 競合他社の状況
5.1 企業シェア分析
5.2 市場シェア
5.2.1 医薬品原体・API
5.2.2 固形製剤
5.2.3 液状製剤
5.2.3.1 非滅菌
5.2.3.2 無菌製剤
5.2.4 半固形製剤
6 企業プロフィール
6.1 Johnson & Johnson Services Inc.
6.1.1 企業スナップショット
6.1.2 会社概要
6.1.3 財務分析
6.1.3.1 純収益、2017-2021年
6.1.3.2 営業利益、2017年-2021年
6.1.3.3 純利益、2017年-2021年
6.1.3.4 ebitda、2017-2021年
6.1.3.5 会社地域別収益マーケットシェア
6.1.3.6 会社事業セグメント分析
6.1.4 サービスベンチマーク
6.1.5 戦略的な展望
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 企業スナップショット
6.2.2 会社概要
6.2.3 財務分析
6.2.3.1 純収益、2017-2021年
6.2.3.2 営業利益、2017年～2021年
6.2.3.3 純利益、2017-2021年
6.2.3.4 ebitda、2017-2021年
6.2.3.5 会社地域別収益マーケットシェア
6.2.3.6 会社の事業セグメント分析
6.2.4 製品ベンチマーク
6.2.5 戦略的な展望
6.3 Pfizer Inc.
6.3.1 企業スナップショット
6.3.2 会社概要
6.3.3 財務分析
6.3.3.1 純収益、2017-2021年
6.3.3.2 営業利益、2017年-2021年
6.3.3.3 純利益、2017-2021年
6.3.3.4 ebitda、2017-2021年
6.3.3.5 各社地域別収益マーケットシェア
6.3.4 サービスベンチマーク
6.3.5 戦略的な展望
6.4 Bayer AG
6.4.1 企業スナップショット
6.4.2 会社概要
6.4.3 財務分析
6.4.3.1 純収益、2017-2021年
6.4.3.2 営業利益、2017年-2021年
6.4.3.3 純利益、2017-2021年
6.4.3.4 ebitda、2017-2021年
6.4.3.5 会社地域別収益マーケットシェア
6.4.3.6 会社の事業セグメント分析
6.4.4 製品ベンチマーク
6.4.5 戦略的な展望
6.5 Novartis AG
6.5.1 企業スナップショット
6.5.2 会社概要
6.5.3 財務分析
6.5.3.1 純収益、2017年-2021年
6.5.3.2 営業利益、2017年-2021年
6.5.3.3 当期純利益、2017年-2021年
6.5.3.4 ebitda、2017-2021年
6.5.3.5 会社地域別収益マーケットシェア
6.5.3.6 企業の事業セグメント分析
6.5.4 サービスベンチマーク
6.5.5 戦略的な展望
6.6 CordenPharma International
6.6.1 企業スナップショット
6.6.2 会社概要
6.6.3 サービスベンチマーキング
6.6.4 戦略的展望
6.7 GSK plc
6.7.1 企業スナップショット
6.7.2 会社概要
6.7.3 財務分析
6.7.3.1 純収益、2017-2021年
6.7.3.2 営業利益、2017年-2021年
6.7.3.3 当期純利益、2017年-2021年
6.7.3.4 ebitda、2017-2021年
6.7.3.5 会社地域別収益マーケットシェア
6.7.3.6 会社の事業セグメント分析
6.7.4 サービスベンチマーク
6.7.5 戦略的な展望
6.8 Sanofi
6.8.1 企業スナップショット
6.8.2 会社概要
6.8.3 財務分析
6.8.3.1 純収益、2017年-2021年
6.8.3.2 営業利益、2017年-2021年
6.8.3.3 当期純利益、2017年-2021年
6.8.3.4 ebitda、2017年-2021年
6.8.3.5 会社地域別収益マーケットシェア
6.8.3.6 会社の事業セグメント分析
6.8.4 サービスベンチマーク
6.8.5 戦略的な展望
6.9 AbbVie Inc.
6.9.1 企業スナップショット
6.9.2 会社概要
6.9.3 財務分析
6.9.3.1 純収益、2017年-2021年
6.9.3.2 営業利益、2017年-2021年
6.9.3.3 純利益、2017-2021年
6.9.3.4 ebitda、2017-2021年
6.9.3.5 会社地域別収益マーケットシェア
6.9.3.6 会社の事業セグメント分析
6.9.4 サービスベンチマーク
6.9.5 戦略的な展望
6.10 Abbott Laboratories
6.10.1 企業スナップショット
6.10.2 会社概要
6.10.3 財務分析
6.10.3.1 純収益、2017年-2021年
6.10.3.2 営業利益、2017年-2021年
6.10.3.3 純利益、2017-2021年
6.10.3.4 ebitda、2017-2021年
6.10.3.5 会社地域別収益マーケットシェア
6.10.3.6 会社の事業セグメント分析
6.10.4 サービスベンチマーク
6.10.5 戦略的な展望
6.11 Thermo Fisher Scientific Inc.
6.11.1 企業スナップショット
6.11.2 会社概要
6.11.3 財務分析
6.11.3.1 純収益、2017年-2021年
6.11.3.2 営業利益、2017年-2021年
6.11.3.3 純利益、2017-2021年
6.11.3.4 ebitda、2017-2021年
6.11.3.5 会社地域別収益マーケットシェア
6.11.3.6 会社の事業セグメント分析
6.11.4 サービスベンチマーク
6.11.5 戦略的な展望
6.12 AstraZeneca
6.12.1 企業スナップショット
6.12.2 会社概要
6.12.3 財務分析
6.12.3.1 純収益、2017年-2021年
6.12.3.2 営業利益、2017年-2021年
6.12.3.3 純利益、2017-2021年
6.12.3.4 ebitda、2017-2021年
6.12.3.5 会社地域別収益マーケットシェア
6.12.3.6 会社の事業セグメント分析
6.12.4 サービスベンチマーク
6.12.5 戦略的な展望
6.13 Eli Lilly and Company
6.13.1 企業スナップショット
6.13.2 会社概要
6.13.3 財務分析
6.13.3.1 純収益、2017年-2021年
6.13.3.2 営業利益、2017年-2021年
6.13.3.3 純利益、2017-2021年
6.13.3.4 ebitda、2017-2021年
6.13.3.5 会社地域別収益マーケットシェア
6.13.3.6 会社の事業セグメント分析
6.13.4 サービスベンチマーク
6.13.5 戦略的な展望
6.14 Gilead Sciences, Inc.
6.14.1 企業スナップショット
6.14.2 会社概要
6.14.3 財務分析
6.14.3.1 純収益、2017年-2021年
6.14.3.2 営業利益、2017年-2021年
6.14.3.3 当期純利益、2017年-2021年
6.14.3.4 ebitda、2017-2021年
6.14.4 サービスベンチマーク
6.14.5 戦略的な展望
6.15 DuPont
6.15.1 企業スナップショット
6.15.2 会社概要
6.15.3 財務分析
6.15.3.1 純収益、2017-2021年
6.15.3.2 営業利益、2017年-2021年
6.15.3.3 純利益、2017-2021年
6.15.3.4 ebitda、2017-2021年
6.15.4 サービスベンチマーク
6.15.5 戦略的な展望
6.16 Novo Nordisk A/S
6.16.1 企業スナップショット
6.16.2 会社概要
6.16.3 財務分析
6.16.3.1 純収益、2017年-2021年
6.16.3.2 営業利益、2017年-2021年
6.16.3.3 当期純利益、2017年-2021年
6.16.3.4 ebitda、2017-2021年
6.16.3.5 会社地域別収益マーケットシェア
6.16.3.6 会社の事業セグメント分析
6.16.4 サービスベンチマーク
6.16.5 戦略的な展望
6.17 Merck KGaA
6.17.1 企業スナップショット
6.17.2 会社概要
6.17.3 財務分析
6.17.3.1 純収益、2017年-2021年
6.17.3.2 営業利益、2017年-2021年
6.17.3.3 当期純利益、2017年-2021年
6.17.3.4 ebitda、2017-2021年
6.17.4 サービスベンチマーク
6.17.5 戦略的な展望
6.18 BD
6.18.1 カンパニースナップショット
6.18.2 会社概要
6.18.3 財務分析
6.18.3.1 純収益、2017-2021年
6.18.3.2 営業利益、2017年-2021年
6.18.3.3 当期純利益、2017年-2021年
6.18.3.4 ebitda、2017-2021年
6.18.3.5 会社地域別収益マーケットシェア
6.18.3.6 会社の事業セグメント分析
6.18.4 サービスベンチマーク
6.18.5 戦略的な展望
6.19 Teva Pharmaceuticals Industries Ltd.
6.19.1 企業スナップショット
6.19.2 会社概要
6.19.3 財務分析
6.19.3.1 純収益、2017年-2021年
6.19.3.2 営業利益、2017年-2021年
6.19.3.3 当期純利益、2017年-2021年
6.19.3.4 ebitda、2017-2021年
6.19.4 サービスベンチマーク
6.19.5 戦略的な展望
6.20 Evonik Industries
6.20.1 企業スナップショット
6.20.2 会社概要
6.20.3 サービス・ベンチマーク
6.20.4 戦略的展望
6.21 UPMファーマシューティカルズ
6.21.1 企業スナップショット
6.21.2 会社概要
6.21.3 サービス・ベンチマーク
6.21.4 戦略的展望
6.22 Baxter Biopharma Solutions
6.22.1 企業スナップショット
6.22.2 会社概要
6.22.3 財務分析
6.22.3.1 純収益、2017年-2021年
6.22.3.2 営業利益、2017年-2021年
6.22.3.3 当期純利益、2017年-2021年
6.22.3.4 ebitda、2017-2021年
6.22.3.5 会社地域別収益マーケットシェア
6.22.3.6 会社の事業セグメント分析
6.22.4 サービスベンチマーク
6.22.5 戦略的な展望
6.23 Boston Scientific Corporation
6.23.1 企業スナップショット
6.23.2 会社概要
6.23.3 財務分析
6.23.3.1 純収益、2017年-2021年
6.23.3.2 営業利益、2017年-2021年
6.23.3.3 当期純利益、2017年-2021年
6.23.3.4 ebitda、2017-2021年
6.23.3.5 会社地域別収益マーケットシェア
6.23.3.6 会社の事業セグメント分析
6.23.4 サービスベンチマーク
6.23.5 戦略的な展望
6.24 Koninklijke DSM N.V.（Royal DSM）
6.24.1 企業スナップショット
6.24.2 会社概要
6.24.3 財務分析
6.24.3.1 純収益、2017年-2021年
6.24.3.2 営業利益、2017年-2021年
6.24.3.3 当期純利益、2017年-2021年
6.24.3.4 ebitda、2017-2021年
6.24.4 サービスベンチマーク
6.24.5 戦略的な展望
6.25 CSL Limited
6.25.1 企業スナップショット
6.25.2 会社概要
6.25.3 財務分析
6.25.3.1 純収益、2017年-2021年
6.25.3.2 営業利益、2017年-2021年
6.25.3.3 当期純利益、2017年-2021年
6.25.3.4 ebitda、2017-2021年
6.25.3.5 会社地域別収益マーケットシェア
6.25.3.6 会社の事業セグメント分析
6.25.4 サービスベンチマーク
6.25.5 戦略的な展望
6.26 Lonza
6.26.1 企業スナップショット
6.26.2 会社概要
6.26.3 財務分析
6.26.3.1 純収益、2017年-2021年
6.26.3.2 営業利益、2017年-2021年
6.26.3.3 当期純利益、2017年-2021年
6.26.3.4 ebitda、2017-2021年
6.26.3.5 会社地域別収益マーケットシェア
6.26.3.6 会社の事業セグメント分析
6.26.4 サービスベンチマーク
6.26.5 戦略的な展望
6.27 McKesson Corporation
6.27.1 企業スナップショット
6.27.2 会社概要
6.27.3 財務分析
6.27.3.1 純収益、2017-2021年
6.27.3.2 営業利益、2017年-2021年
6.27.3.3 純利益、2017-2021年
6.27.3.4 ebitda、2017-2021年
6.27.3.5 会社地域別収益マーケットシェア
6.27.3.6 会社の事業セグメント分析
6.27.4 製品ベンチマーク
6.27.5 戦略的な展望
6.28 Edwards Lifesciences Corporation
6.28.1 企業スナップショット
6.28.2 会社概要
6.28.3 財務分析
6.28.3.1 純収益、2017年-2021年
6.28.3.2 営業利益、2017年-2021年
6.28.3.3 当期純利益、2017年-2021年
6.28.3.4 ebitda、2017-2021年
6.28.3.5 会社地域別収益マーケットシェア
6.28.3.6 会社の事業セグメント分析
6.28.4 製品ベンチマーク
6.28.5 戦略的展望
6.29 Nipro Corporation
6.29.1 企業スナップショット
6.29.2 会社概要
6.29.3 サービスベンチマーク
6.29.4 戦略的展望
6.30 PPD Inc.
6.30.1 企業スナップショット
6.30.2 会社概要
6.30.3 サービスベンチマーキング
6.30.4 戦略的展望
6.31 Grifols
6.31.1 企業スナップショット
6.31.2 会社概要
6.31.3 財務分析
6.31.3.1 純収益、2017年-2021年
6.31.3.2 営業利益、2017年-2021年
6.31.3.3 当期純利益、2017-2021年
6.31.3.4 ebitda、2017-2021年
6.31.4 サービスベンチマーク
6.31.5 戦略的な展望
6.32 bioMérieux
6.32.1 企業スナップショット
6.32.2 会社概要
6.32.3 財務分析
6.32.3.1 純収益、2017年-2021年
6.32.3.2 営業利益、2017年-2021年
6.32.3.3 当期純利益、2017年-2021年
6.32.3.4 ebitda、2017-2021年
6.32.3.5 会社地域別収益マーケットシェア
6.32.3.6 会社の事業セグメント分析
6.32.4 製品ベンチマーク
6.32.5 戦略的な展望
6.33 Aurobindo Pharma
6.33.1 企業スナップショット
6.33.2 会社概要
6.33.3 サービスベンチマーク
6.33.4 戦略的展望
6.34 Dr. Reddy's Laboratories Ltd.
6.34.1 企業スナップショット
6.34.2 会社概要
6.34.3 財務分析
6.34.3.1 純収益、2017年-2021年
6.34.3.2 営業利益、2017年-2021年
6.34.3.3 当期純利益、2017年-2021年
6.34.3.4 ebitda、2017-2021年
6.34.3.5 会社地域別収益マーケットシェア
6.34.3.6 会社の事業セグメント分析
6.34.4 サービスベンチマーク
6.34.5 戦略的な展望
6.35 WuXi AppTec
6.35.1 企業スナップショット
6.35.2 会社概要
6.35.3 サービスベンチマーキング
6.35.4 戦略的展望
6.36 Huapont Life Sciences Co Ltd.
6.36.1 企業スナップショット
6.36.2 会社概要
6.36.3 サービスベンチマーキング
6.37 ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.
6.37.1 企業スナップショット
6.37.2 会社概要
6.37.3 サービスベンチマーキング
6.37.4 戦略的な展望
6.38 Alkermes
6.38.1 企業スナップショット
6.38.2 会社概要
6.38.3 財務分析
6.38.3.1 純収益、2017年-2021年
6.38.3.2 営業利益、2017年-2021年
6.38.3.3 当期純利益、2017年-2021年
6.38.3.4 ebitda、2017-2021年
6.38.4 サービスベンチマーク
6.38.5 戦略的な展望
6.39 Emergent BioSolutions
6.39.1 企業スナップショット
6.39.2 会社概要
6.39.3 財務分析
6.39.3.1 純収益、2017年-2021年
6.39.3.2 営業利益、2017年-2021年
6.39.3.3 当期純利益、2017年-2021年
6.39.3.4 ebitda、2017-2021年
6.39.4 サービスベンチマーク
6.39.5 戦略的な展望
6.40 Divi's Laboratories Limited
6.40.1 企業スナップショット
6.40.2 会社概要
6.40.3 サービスベンチマーキング
6.41 Bavarian Nordic
6.41.1 企業スナップショット
6.41.2 会社概要
6.41.3 財務分析
6.41.3.1 純収益、2017-2021年
6.41.3.2 営業利益、2017年-2021年
6.41.3.3 当期純利益、2017年-2021年
6.41.3.4 ebitda、2017-2021年
6.41.3.5 会社地域別収益マーケットシェア
6.41.3.6 会社の事業セグメント分析
6.41.4 サービスベンチマーク
6.41.5 戦略的な展望
6.42 Strides Pharma Science Limited
6.42.1 企業スナップショット
6.42.2 会社概要
6.42.3 サービスベンチマーキング
6.42.4 戦略的展望
6.43 Consort Medical plc
6.43.1 企業スナップショット
6.43.2 会社概要
6.43.3 サービスベンチマーキング
6.43.4 戦略的展望
6.44 Catalent Inc.
6.44.1 企業スナップショット
6.44.2 会社概要
6.44.3 財務分析
6.44.3.1 純収益、2017年-2021年
6.44.3.2 営業利益、2017年-2021年
6.44.3.3 当期純利益、2017年-2021年
6.44.3.4 ebitda、2017-2021年
6.44.3.5 会社地域別収益マーケットシェア
6.44.3.6 会社の事業セグメント分析
6.44.4 サービスベンチマーク
6.44.5 戦略的な展望
6.45 Moderna Inc.
6.45.1 企業スナップショット
6.45.2 会社概要
6.45.3 財務分析
6.45.3.1 純収益、2017年-2021年
6.45.3.2 営業利益、2017年-2021年
6.45.3.3 当期純利益、2017-2021年
6.45.3.4 ebitda、2017-2021年
6.45.4 サービスベンチマーク
6.45.5 戦略的な展望
6.46 Avid Bioservices, Inc.
6.46.1 企業スナップショット
6.46.2 会社概要
6.46.3 財務分析
6.46.3.1 純収益、2017年-2021年
6.46.3.2 営業利益、2017年-2021年
6.46.3.3 当期純利益、2017年-2021年
6.46.3.4 ebitda、2017-2021年
6.46.4 サービスベンチマーク
6.46.5 戦略的な展望
6.47 Novavax
6.47.1 企業スナップショット
6.47.2 会社概要
6.47.3 財務分析
6.47.3.1 純収益、2017年-2021年
6.47.3.2 営業利益、2017年-2021年
6.47.3.3 当期純利益、2017年-2021年
6.47.3.4 ebitda、2017-2021年
6.47.4 サービスベンチマーク
6.47.5 戦略的な展望
6.48 INOVIO Pharmaceuticals
6.48.1 企業スナップショット
6.48.2 会社概要
6.48.3 財務分析
6.48.3.1 純収益、2017年-2021年
6.48.3.2 営業利益、2017年-2021年
6.48.3.3 当期純利益、2017年-2021年
6.48.3.4 ebitda、2017年-2021年
6.48.4 サービスベンチマーク
6.48.5 戦略的な展望
6.49 VBI Vaccines Inc.
6.49.1 企業スナップショット
6.49.2 会社概要
6.49.3 財務分析
6.49.3.1 純収益、2017年-2021年
6.49.3.2 営業利益、2017年-2021年
6.49.3.3 当期純利益、2017-2021年
6.49.3.4 ebitda、2017-2021年
6.49.4 サービスベンチマーク
6.49.5 戦略的な展望
6.50 Fresenius SE&Co. KGaA
6.50.1 企業スナップショット
6.50.2 会社概要
6.50.3 財務分析
6.50.3.1 純収益、2017年-2021年
6.50.3.2 営業利益、2017年-2021年
6.50.3.3 当期純利益、2017年-2021年
6.50.3.4 ebitda、2017-2021年
6.50.3.5 会社地域別収益マーケットシェア
6.50.3.6 会社の事業セグメント分析
6.50.4 サービスベンチマーク
6.50.5 戦略的な展望
7 結論と提言
7.1 ヴィジョンゲインからの結論
7.2 市場プレイヤーへの提言
7.2.4 バイオ医薬品の製造需要が2022-2032年の成長を牽引する
表の一覧
Table 1 Pharmaceutical Contract Manufacturing Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery Scenario)
Table 3 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022 2032 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery Scenario)
Table 4 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery Scenario)
Table 5 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery Scenario)
Table 6 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%))
Table 7 Market Share of Contract Manufacturing Companies Providing Bulk Drugs and APIs, 2021 (%)
Table 8 Market Share of Contract Manufacturing Companies Providing Solid Dosage Forms, 2021, (%)
Table 9 Market Share of Contract Manufacturing Companies Providing Nonsterile Liquid Dosage Forms, 2021 (%)
Table 10 Market Share of Contract Manufacturing Companies Providing Sterile Liquid Dosage Forms, 2021
Table 11 Market Share of Contract Manufacturing Companies Providing Sterile Liquid Dosage Forms, 2021
Table 12 Johnson & Johnson Services Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 13 Johnson & Johnson Services Inc.: Service Benchmarking
Table 14 Johnson & Johnson Services Inc.: Strategic Outlook
Table 15 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 16 F. Hoffmann-La Roche Ltd: Service Benchmarking
Table 17 F. Hoffmann-La Roche Ltd: Strategic Outlook
Table 18 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 19 Pfizer Inc.: Service Benchmarking
Table 20 Pfizer Inc.: Strategic Outlook
Table 21 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 22 Bayer AG: Service Benchmarking
Table 23 Bayer AG: Strategic Outlook
Table 24 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 25 Novartis AG: Service Benchmarking
Table 26 Novartis AG: Strategic Outlook
Table 27 CordenPharma International: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 28 CordenPharma International: Service Benchmarking
Table 29 CordenPharma International: Strategic Outlook
Table 30 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 31 GSK plc: Service Benchmarking
Table 32 GSK plc: Strategic Outlook
Table 33 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 34 Sanofi: Service Benchmarking
Table 35 Sanofi: Strategic Outlook
Table 36 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 37 AbbVie Inc.: Service Benchmarking
Table 38 AbbVie Inc.: Strategic Outlook
Table 39 Abbott Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 40 Abbott Laboratories: Service Benchmarking
Table 41 Abbott Laboratories: Strategic Outlook
Table 42 Thermo Fisher Scientific Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 43 Thermo Fisher Scientific Inc.: Service Benchmarking
Table 44 Thermo Fisher Scientific Inc.: Strategic Outlook
Table 45 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 46 AstraZeneca: Service Benchmarking
Table 47 AstraZeneca: Strategic Outlook
Table 48 Eli Lily and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 49 Eli Lily and Company: Service Benchmarking
Table 50 Eli Lily and Company: Strategic Outlook
Table 51 Gilead Science Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 52 Gilead Science Inc.: Service Benchmarking
Table 53 Gilead Science Inc.: Strategic Outlook
Table 54 DuPont: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 55 DuPont: Service Benchmarking
Table 56 DuPont: Strategic Outlook
Table 57 Novo Nordisk A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 58 Novo Nordisk A/S: Service Benchmarking
Table 59 Novo Nordisk A/S: Strategic Outlook
Table 60 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 61 Merck KGaA: Service Benchmarking
Table 62 Merck KGaA: Strategic Outlook
Table 63 BD: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 64 BD: Service Benchmarking
Table 65 BD: Strategic Outlook
Table 66 Teva Pharmaceutical: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 67 Teva Pharmaceutical: Service Benchmarking
Table 68 Teva Pharmaceutical: Strategic Outlook
Table 69 Evonik Industries: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 Evonik Industries: Service Benchmarking
Table 71 Evonik Industries: Strategic Outlook
Table 72 UPM Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 UPM Pharmaceuticals: Service Benchmarking
Table 74 UPM Pharmaceuticals: Strategic Outlook
Table 75 Baxter Biopharma Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 Baxter Biopharma Solutions: Service Benchmarking
Table 77 Baxter Biopharma Solutions: Strategic Outlook
Table 78 Boston Scientific Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Boston Scientific Corporation: Service Benchmarking
Table 80 Boston Scientific Corporation: Strategic Outlook
Table 81 Koninklijke DSM N.V: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Koninklijke DSM N.V: Service Benchmarking
Table 83 Koninklijke DSM N.V: Strategic Outlook
Table 84 CSL Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 CSL Limited: Service Benchmarking
Table 86 CSL Limited: Strategic Outlook
Table 87 Lonza: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Lonza: Service Benchmarking
Table 89 Lonza: Strategic Outlook
Table 90 McKesson Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 McKesson Corporation: Service Benchmarking
Table 92 McKesson Corporation: Strategic Outlook
Table 93 Edwards Lifesciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Edwards Lifesciences: Service Benchmarking
Table 95 Edwards Lifesciences: Strategic Outlook
Table 96 Nipro Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Nipro Corporation: Service Benchmarking
Table 98 Nipro Corporation: Strategic Outlook
Table 99 PPD Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 PPD Inc.: Service Benchmarking
Table 101 PPD Inc.: Strategic Outlook
Table 102 Grifols: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Grifols: Service Benchmarking
Table 104 Grifols: Strategic Outlook
Table 105 bioMérieux: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Table 110 bioMérieux: Service Benchmarking
Table 107 bioMérieux: Strategic Outlook
Table 108 Aurobindo Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 Aurobindo Pharma: Service Benchmarking
Table 110 Aurobindo Pharma: Strategic Outlook
Table 111 Dr. Reddy's Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 112 Dr. Reddy's Laboratories Ltd.: Service Benchmarking
Table 113 Dr. Reddy's Laboratories Ltd.: Strategic Outlook
Table 114 Wuxi AppTec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Wuxi AppTec: Service Benchmarking
Table 116 Wuxi AppTec: Strategic Outlook
Table 117 Huapont Life Sciences Co Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Huapont Life Sciences Co Ltd: Service Benchmarking
Table 119 ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 120 ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.: Service Benchmarking
Table 121 ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.: Strategic Outlook
Table 122 Alkermes: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Alkermes: Service Benchmarking
Table 124 Alkermes: Strategic Outlook
Table 125 Emergent BioSolutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Emergent BioSolutions: Service Benchmarking
Table 127 Emergent BioSolutions: Strategic Outlook
Table 128 Divi’s Laboratories Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 129 Divi’s Laboratories Limited: Service Benchmarking
Table 130 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Bavarian Nordic: Service Benchmarking
Table 132 Bavarian Nordic K: Strategic Outlook
Table 133 Strides Pharma Science Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 134 Strides Pharma Science Ltd: Service Benchmarking
Table 135 Strides Pharma Science Limited: Strategic Outlook
Table 136 Consort Medical plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 137 Consort Medical plc: Service Benchmarking
Table 138 Consort Medical plc: Strategic Outlook
Table 139 Catalent Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 140 Catalent Inc: Service Benchmarking
Table 141 Catalent Pharma Solutions Inc: Strategic Outlook
Table 142 Moderna Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 143 Moderna Inc.: Service Benchmarking
Table 144 Moderna Inc.: Strategic Outlook
Table 145 Avid Bioservices, Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 146 Avid Bioservices, Inc: Service Benchmarking
Table 147 Avid Bioservices, Inc: Strategic Outlook
Table 148 Novavax: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 149 Novavax: Service Benchmarking
Table 150 Novavax: Strategic Outlook
Table 151 INOVIO Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 152 INOVIO Pharmaceuticals: Service Benchmarking
Table 153 INOVIO Pharmaceuticals: Strategic Outlook
Table 154 VBI Vaccines Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 155 VBI Vaccines Biotechnology: Service Benchmarking
Table 156 VBI Vaccines Biotechnology: Strategic Outlook
Table 157 Fresenius SE&Co. KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 158 Fresenius SE&Co. KGaA: Service Benchmarking
Table 159 Fresenius SE&Co. KGaA: Strategic Outlook
図の一覧
Figure 1 Pharmaceutical Contract Manufacturing Organisations (CMO): Market Dynamics
Figure 2 COVID Impact Analysis: Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Recovery Scenarios
Figure 3 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%)): “V” Shaped Recovery
Figure 4 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%)): “U” Shaped Recovery
Figure 5 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%)): “W” Shaped Recovery
Figure 6 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%)): “L” Shaped Recovery
Figure 7 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market: Porter’s Five Forces Analysis
Figure 8 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Forecast by Region 2022, 2027, 2032 (Revenue, CAGR%)
Figure 9 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%))
Figure 10 Johnson & Johnson Services Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 11 Johnson & Johnson Services Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 12 Johnson & Johnson Services Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 13 Johnson & Johnson Services Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 14 Johnson & Johnson Services Inc.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 15 Johnson & Johnson Services Inc.: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 16 F. Hoffmann-La Roche Ltd: Revenue, 2017-2021 (US$ million, AGR%)
Figure 17 F. Hoffmann-La Roche Ltd: Operating Income 2017-2021 (US$ million, AGR%)
Figure 18 F. Hoffmann-La Roche Ltd: Net Income 2017-2021 (US$ million, AGR%)
Figure 19 F. Hoffmann-La Roche Ltd: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 20 F. Hoffmann-La Roche Ltd: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 21 F. Hoffmann-La Roche Ltd: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Source: Visiongain Reports Ltd., 2022
Figure 22 Pfizer Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 23 Pfizer Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 24 Pfizer Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 25 Pfizer Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 26 Pfizer Inc.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 27 Bayer AG: Revenue, 2017-2021 (US$ million, AGR%)
Figure 28 Bayer AG: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 29 Bayer AG: Net Income 2017-2021 (US$ million, AGR%)
Figure 30 Bayer AG: EBITDA, 2017-2021 (US$million)
Figure 31 Bayer AG: Company Regional Revenue Market Share Analysis 2021(%)
Figure 32 Bayer AG: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 33 Novartis AG: Revenue, 2017-2021 (US$ million, AGR%)
Figure 34 Novartis AG: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 35 Novartis AG: Net Income 2017-2021 (US$ million, AGR%)
Figure 36 Novartis AG: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 37 Novartis AG: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 38 Novartis AG: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 39 GSK plc: Revenue, 2017-2021 (US$ million, AGR%)
Figure 40 GSK plc: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 41 GSK plc: Net Income 2017-2021 (US$ million, AGR%)
Figure 42 GSK plc: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 43 GSK plc: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 44 GSK plc: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 45 Sanofi: Revenue, 2017-2021 (US$ million, AGR%)
Figure 46 Sanofi: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 47 Sanofi: Net Income 2017-2021 (US$ million, AGR%)
Figure 48 Sanofi: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 49 Sanofi: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 50 Sanofi: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 51 AbbVie Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 52 AbbVie Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 53 AbbVie Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 54 AbbVie Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 55 AbbVie Inc.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 56 AbbVie Inc.: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 57 Abbott Laboratories: Revenue, 2017-2021 (US$ million, AGR%)
Figure 58 Abbott Laboratories: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 59 Abbott Laboratories: Net Income 2017-2021 (US$ million, AGR%)
Figure 60 Abbott Laboratories: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 61 Abbott Laboratories: Company Regional Revenue Market Share Analysis 2021(%)
Figure 62 Abbott Laboratories: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 63 Thermo Fisher Scientific Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 64 Thermo Fisher Scientific Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 65 Thermo Fisher Scientific Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 66 Thermo Fisher Scientific Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 67 Thermo Fisher Scientific Inc.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 68 Thermo Fisher Scientific Inc.: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 69 AstraZeneca: Revenue, 2017-2021 (US$ million, AGR%)
Figure 70 AstraZeneca: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 71 AstraZeneca: Net Income 2017-2021 (US$ million, AGR%)
Figure 72 AstraZeneca: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 73 AstraZeneca: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 74 AstraZeneca: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 75 Eli Lily and Company: Revenue, 2017-2021 (US$ million, AGR%)
Figure 76 Eli Lily and Company: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 77 Eli Lily and Company: Net Income 2017-2021 (US$ million, AGR%)
Figure 78 Eli Lily and Company: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 79 Eli Lily and Company: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 80 Eli Lily and Company: Company Revenue Breakdown by Business Segments Analysis 2021(%)
Figure 81 Gilead Science Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 82 Gilead Science Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 83 Gilead Science Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 84 Gilead Science Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 85 DuPont: Revenue, 2017-2021 (US$ million, AGR%)
Figure 86 DuPont: Operating Income, 2017-2021 (US$ million)
Figure 87 DuPont: Net Income 2017-2021 (US$ million)
Figure 88 DuPont: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 89 Novo Nordisk A/S: Revenue, 2017-2021 (US$ million, AGR%)
Figure 90 Novo Nordisk A/S: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 91 Novo Nordisk A/S: Net Income 2017-2021 (US$ million, AGR%)
Figure 92 Novo Nordisk A/S: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 93 Novo Nordisk A/S: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 94 Novo Nordisk A/S: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 95 Merck KGaA: Revenue, 2017-2021 (US$ million, AGR%)
Figure 96 Merck KGaA: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 97 Merck KGaA: Net Income 2017-2021 (US$ million, AGR%)
Figure 98 Merck KGaA: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 99 Merck KGaA: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 100 Merck KGaA: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 101 BD: Revenue, 2017-2021 (US$ million, AGR%)
Figure 102 BD: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 103 BD: Net Income 2017-2021 (US$ million, AGR%)
Figure 104 BD: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 105 BD: Regional Revenue Market Share Analysis 2021 (%)
Figure 106 BD: Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 107 Teva Pharmaceutical: Revenue, 2017-2021 (US$ million, AGR%)
Figure 108 Teva Pharmaceutical: Operating Income, 2017-2021 (US$ million)
Figure 109 Teva Pharmaceutical: Net Income 2017-2021 (US$ million)
Figure 110 Teva Pharmaceutical: EBITDA, 2017-2021 (US$ million)
Figure 111 Baxter Biopharma Solutions: Revenue, 2017-2021 (US$ million, AGR%)
Figure 112 Baxter Biopharma Solutions: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 113 Baxter Biopharma Solutions: Net Income 2017-2021 (US$ million, AGR%)
Figure 114 Baxter Biopharma Solutions: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 115 Baxter Biopharma Solutions: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 116 Baxter Biopharma Solutions: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 117 Boston Scientific Corporation: Revenue, 2017-2021 (US$ million, AGR%)
Figure 118 Boston Scientific Corporation: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 119 Boston Scientific Corporation: Net Income 2017-2021 (US$ million)
Figure 120 Boston Scientific Corporation: EBITDA, 2017-2021 (US$ million)
Figure 121 Boston Scientific Corporation: Company Regional Revenue Market Share Analysis 2021(US$Mn)
Figure 122 Boston Scientific Corporation: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 123 Koninklijke DSM N.V: Revenue, 2017-2021 (US$ million, AGR%)
Figure 124 Koninklijke DSM N.V: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 125 Koninklijke DSM N.V: Net Income 2017-2021 (US$ million, AGR%)
Figure 126 Koninklijke DSM N.V: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 127 CSL Limited: Revenue, 2017-2021 (US$ million, AGR%)
Figure 128 CSL Limited: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 129 CSL Limited: Net Income 2017-2021 (US$ million, AGR%)
Figure 130 CSL Limited: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 131 CSL Limited: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 132 CSL Limited: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 133 Lonza: Revenue, 2017-2021 (US$ million, AGR%)
Figure 134 Lonza: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 135 Lonza: Net Income 2017-2021 (US$ million, AGR%)
Figure 136 Lonza: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 137 Lonza: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 138 Lonza Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 139 McKesson Corporation: Revenue, 2017-2021 (US$ million, AGR%)
Figure 140 McKesson Corporation: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 141 McKesson Corporation: Net Income 2017-2021 (US$ million, AGR%)
Figure 142 McKesson Corporation: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 143 McKesson Corporation: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 144 McKesson Corporation: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 145 Edwards Lifesciences: Revenue, 2017-2021 (US$ million, AGR%)
Figure 146 Edwards Lifesciences: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 147 Edwards Lifesciences: Net Income 2017-2021 (US$ million, AGR%)
Figure 148 Edwards Lifesciences: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 149 Edwards Lifesciences: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 150 Edwards Lifesciences: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 151 Grifols: Revenue, 2017-2021 (US$ million, AGR%)
Figure 152 Grifols: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 153 Grifols: Net Income 2017-2021 (US$ million, AGR%)
Figure 154 Grifols: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 155 bioMérieux: Revenue, 2017-2021 (US$ million, AGR%)
Figure 156 bioMérieux: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 157 bioMérieux: Net Income 2017-2021 (US$ million, AGR%)
Figure 158 bioMérieux: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 159 bioMérieux: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 160 bioMérieux: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 161 Dr. Reddy's Laboratories Ltd.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 162 Dr. Reddy's Laboratories Ltd.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 163 Dr. Reddy's Laboratories Ltd.: Net Income 2017-2021 (US$ million, AGR%)
Figure 164 Dr. Reddy's Laboratories Ltd.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 165 Dr. Reddy's Laboratories Ltd.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 166 Dr. Reddy's Laboratories Ltd. Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 167 Alkermes: Revenue, 2017-2021 (US$ million, AGR%)
Figure 168 Alkermes: Operating Income, 2017-2021 (US$ million)
Figure 169 Alkermes: Net Income 2017-2021 (US$ million)
Figure 170 Alkermes: EBITDA, 2017-2021 (US$ million)
Figure 171 Emergent BioSolutions: Revenue, 2017-2021 (US$ million, AGR%)
Figure 172 Emergent BioSolutions: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 173 Emergent BioSolutions: Net Income 2017-2021 (US$ million, AGR%)
Figure 174 Emergent BioSolutions: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 175 Bavarian Nordic: Revenue, 2017-2021 (US$ million, AGR%)
Figure 176 Bavarian Nordic: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 177 Bavarian Nordic: Net Income 2017-2021 (US$ million, AGR%)
Figure 178 Bavarian Nordic: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 179 Bavarian Nordic: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 180 Bavarian Nordic: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 181 Catalent Inc: Revenue, 2017-2021 (US$ million, AGR%)
Figure 182 Catalent Inc: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 183 Catalent Inc: Net Income 2017-2021 (US$ million, AGR%)
Figure 184 Catalent Inc: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 185 Catalent Inc: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 186 Catalent Inc: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 187 Moderna Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 188 Moderna Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 189 Moderna Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 190 Moderna Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 191 Avid Bioservices, Inc: Revenue, 2017-2021 (US$ million, AGR%)
Figure 192 Avid Bioservices, Inc: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 193 Avid Bioservices, Inc: Net Income 2017-2021 (US$ million, AGR%)
Figure 194 Avid Bioservices, Inc: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 195 Novavax: Revenue, 2017-2021 (US$ million, AGR%)
Figure 196 Novavax Operating Income, 2017-2021 (US$ million)
Figure 197 Novavax: Net Income 2017-2021 (US$ million)
Figure 198 Novavax: EBITDA, 2017-2021 (US$ million)
Figure 199 INOVIO Pharmaceuticals: Revenue, 2017-2021 (US$ million, AGR%)
Figure 200 INOVIO Pharmaceuticals: Operating Income, 2017-2021 (US$ million)
Figure 201 INOVIO Pharmaceuticals: Net Income 2017-2021 (US$ million)
Figure 202 INOVIO Pharmaceuticals: EBITDA, 2017-2021 (US$ million)
Figure 203 VBI Vaccines Inc.: Revenue, 2017-2021 (US$ million)
Figure 204 VBI Vaccines Inc.: Operating Income, 2017-2021 (US$ million)
Figure 205 VBI Vaccines Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 206 VBI Vaccines Inc.: EBITDA, 2017-2021 (US$ million)
Figure 207 Fresenius SE&Co. KGaA: Revenue, 2017-2021 (US$ million, AGR%)
Figure 208 Fresenius SE&Co. KGaA: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 209 Fresenius SE&Co. KGaA: Net Income 2017-2021 (US$ million, AGR%)
Figure 210 Fresenius SE&Co. KGaA: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 211 Fresenius SE&Co. KGaA: Regional Market Share 2021 (%)
Figure 212 Fresenius SE&Co. KGaA: Business Segment Share (%), 2021
ページTOPに戻る
Summary
Report Details
The Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
The pharmaceutical industry is going through significant changes that are altering its business models, according to the Visiongain analyst. This represents one of the new opportunities for market participants in the global pharmaceutical contract manufacturing organisations. According to Visiongain analysis, the pharmaceutical contract manufacturing organisations (CMOs) market is estimated to be valued at US$1,04,396 million in 2022 and is projected to reach a market value of US$2,03,240 million by 2032.
Growing Demand and Acceptability of Biosimilars Can Be Seen as a Big Opportunity for Pharma CMOs
Growing demand and acceptability of biosimilars can be seen as a big opportunity for contract manufacturing and research organisations. The requirement of affordable healthcare and upcoming patent expiries of innovative biologic drugs offers significant opportunities for biosimilars. Large pharma and biopharma companies see a huge opportunity in biosimilars. Rather than jump into the market on their own, most are interested in sharing their risks and working with collaborators. They are forming joint ventures or partnerships with the outsourcing providers. For Instance, in March 2022, Johnson & Johnson completed a historic agreement between Janssen Pharmaceuticals, Inc. and South African manufacturer Aspen SA Operations (Pty) Ltd to enable the first COVID-19 vaccine to be manufactured and made available by an African company for people living in Africa, with the goal of increasing COVID-19 vaccination rates across the continent.
What Questions Should You Ask before Buying a Market Research Report?
• How is the pharmaceutical contract manufacturing organisations (CMOs) market evolving?
• What is driving and restraining the pharmaceutical contract manufacturing organisations (CMOs) market?
• How will each pharmaceutical contract manufacturing organisations (CMOs) submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading pharmaceutical contract manufacturing organisations (CMOs) markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?
• What are the pharmaceutical contract manufacturing organisations (CMOs) projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of pharmaceutical contract manufacturing organisations (CMOs) projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the pharmaceutical contract manufacturing organisations (CMOs) market?
• Where is the pharmaceutical contract manufacturing organisations (CMOs) market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the pharmaceutical contract manufacturing organisations (CMOs) market today, and over the next 10 years:
• Our 370-page report provides 159 tables, 212 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional growth analysis.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the top 50 pharmaceutical contract manufacturing organisations (CMOs) market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), PEST Analysis, Porter’s Five Forces Analysis
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regions
• North America
• Europe
• Asia Pacific
• South America
• Middle East and Africa
The report also includes profiles and for some of the leading companies in the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• Abbott Laboratories
• AbbVie Inc.
• Alkermes
• AstraZeneca
• Aurobindo Pharma
• Avid Bioservices, Inc.
• Bavarian Nordic
• Baxter Biopharma Solutions
• Bayer AG
• BD
• bioMérieux
• Boston Scientific Corporation
• CordenPharma International
• Catalent Inc.
• Consort Medical plc
• CSL Limited
• Divi’s Laboratories Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Dupont
• Edwards Lifesciences Corporation
• Eli Lilly and Company
• Emergent BioSolutions
• Evonik Industries
• F. Hoffmann-La Roche Ltd.
• Fresenius SE&Co. KGaA
• Gilead Sciences, Inc.
• GSK plc
• Grifols
• Huapont Life Sciences Co Ltd.
• INOVIO Pharmaceuticals
• Johnson & Johnson Services Inc.
• Koninklijke DSM N.V. (Royal DSM)
• Lonza
• McKesson Corporation
• Merck KGaA
• Moderna Inc.
• Nipro Corporation
• Novartis AG
• Novavax
• Novo Nordisk A/S
• Pfizer Inc.
• PPD Inc.
• Sanofi
• Strides Pharma Science Limited
• Teva Pharmaceuticals Industries Ltd.
• Thermo Fisher Scientific Inc.
• UPM Pharmaceuticals
• VBI Vaccines Inc.
• WuXi AppTec
• ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.
Overall world revenue for Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032 in terms of value the market will surpass US$1,04,396 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022 report help you?
In summary, our 370-page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032 Market, with forecasts and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2032 for five regional markets – See forecasts for the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, South America, Middle East & Africa.
• Prospects for established firms and those seeking to enter the market – including company profiles for 50 of the major companies involved in the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
ページTOPに戻る
Table of Contents
Table of Contents
1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Biosimilars Are Becoming Increasingly Popular
3.2.1.2 Increased Concentration on Orphan and Specialty Drugs
3.2.1.3 Demand for Formulation Development Services is Growing
3.2.1.4 Biopharmaceutical Companies Strive for Strategic Collaboration with Drug Delivery Technology Firms
3.2.1.5 Continued Concentration on Productivity
3.2.1.6 Advantage of Cost Savings is Driving the Market Growth
3.2.1.7 To Mitigate Risk Associated to New Drug Development
3.2.2 Market Restraining Factors
3.2.2.1 Product and Process Development is a Challenge
3.2.2.2 The Main Challenge for the CMOs is to Attract Companies Ready to Invest
3.2.2.3 Stringent Regulations Are Hindering the Market Growth
3.2.2.4 Pharmaceutical Manufacturers Are Facing Big Revenue Challenges with the Patent Expirations
3.2.2.5 Challenge Related to the High R&D Expenditures
3.2.2.6 Backwards Compatibility for Generics Manufacturers
3.2.3 Market Opportunities
3.2.3.1 Manufacturing and Packaging Capabilities Are Lacking
3.2.3.2 Pharma Firms will Continue to Look for Ways to Reduce Drug Costs
3.2.3.3 New Drug Delivery Technologies Are Required
3.2.3.4 Chemical APIs Will See a Resurgence Following the Shift in Focus to Biological APIs
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PESTLE Analysis
3.5.1 Political
3.5.2 Economic
3.5.3 Social
3.5.4 Technological
3.5.5 Environmental
3.5.6 Legal
4 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Analysis by Region
4.1 Key Findings
4.2 Regional Market Size Estimation and Forecast
5 Competitive Landscape
5.1 Company Share Analysis
5.2 Market Shares
5.2.1 Bulk Drugs and APIs
5.2.2 Solid Dosage Forms
5.2.3 Liquid Dosage Forms
5.2.3.1 Non-Sterile
5.2.3.2 Sterile
5.2.4 Semi-Solid Dosage Forms
6 Company Profiles
6.1 Johnson & Johnson Services Inc.
6.1.1 Company Snapshot
6.1.2 Company Overview
6.1.3 Financial Analysis
6.1.3.1 Net Revenue, 2017-2021
6.1.3.2 Operating Income, 2017-2021
6.1.3.3 Net Income, 2017-2021
6.1.3.4 EBITDA, 2017-2021
6.1.3.5 Company Regional Revenue Market Share
6.1.3.6 Company Business Segment Analysis
6.1.4 Service Benchmarking
6.1.5 Strategic Outlook
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Snapshot
6.2.2 Company Overview
6.2.3 Financial Analysis
6.2.3.1 Net Revenue, 2017-2021
6.2.3.2 Operating Income, 2017-2021
6.2.3.3 Net Income, 2017-2021
6.2.3.4 EBITDA, 2017-2021
6.2.3.5 Company Regional Revenue Market Share
6.2.3.6 Company Business Segment Analysis
6.2.4 Product Benchmarking
6.2.5 Strategic Outlook
6.3 Pfizer Inc.
6.3.1 Company Snapshot
6.3.2 Company Overview
6.3.3 Financial Analysis
6.3.3.1 Net Revenue, 2017-2021
6.3.3.2 Operating Income, 2017-2021
6.3.3.3 Net Income, 2017-2021
6.3.3.4 EBITDA, 2017-2021
6.3.3.5 Company Regional Revenue Market Share
6.3.4 Service Benchmarking
6.3.5 Strategic Outlook
6.4 Bayer AG
6.4.1 Company Snapshot
6.4.2 Company Overview
6.4.3 Financial Analysis
6.4.3.1 Net Revenue, 2017-2021
6.4.3.2 Operating Income, 2017-2021
6.4.3.3 Net Income, 2017-2021
6.4.3.4 EBITDA, 2017-2021
6.4.3.5 Company Regional Revenue Market Share
6.4.3.6 Company Business Segments Analysis
6.4.4 Product Benchmarking
6.4.5 Strategic Outlook
6.5 Novartis AG
6.5.1 Company Snapshot
6.5.2 Company Overview
6.5.3 Financial Analysis
6.5.3.1 Net Revenue, 2017-2021
6.5.3.2 Operating Income, 2017-2021
6.5.3.3 Net Income, 2017-2021
6.5.3.4 EBITDA, 2017-2021
6.5.3.5 Company Regional Revenue Market Share
6.5.3.6 Company Business Segments Analysis
6.5.4 Service Benchmarking
6.5.5 Strategic Outlook
6.6 CordenPharma International
6.6.1 Company Snapshot
6.6.2 Company Overview
6.6.3 Service Benchmarking
6.6.4 Strategic Outlook
6.7 GSK plc
6.7.1 Company Snapshot
6.7.2 Company Overview
6.7.3 Financial Analysis
6.7.3.1 Net Revenue, 2017-2021
6.7.3.2 Operating Income, 2017-2021
6.7.3.3 Net Income, 2017-2021
6.7.3.4 EBITDA, 2017-2021
6.7.3.5 Company Regional Revenue Market Share
6.7.3.6 Company Business Segments Analysis
6.7.4 Service Benchmarking
6.7.5 Strategic Outlook
6.8 Sanofi
6.8.1 Company Snapshot
6.8.2 Company Overview
6.8.3 Financial Analysis
6.8.3.1 Net Revenue, 2017-2021
6.8.3.2 Operating Income, 2017-2021
6.8.3.3 Net Income, 2017-2021
6.8.3.4 EBITDA, 2017-2021
6.8.3.5 Company Regional Revenue Market Share
6.8.3.6 Company Business Segments Analysis
6.8.4 Service Benchmarking
6.8.5 Strategic Outlook
6.9 AbbVie Inc.
6.9.1 Company Snapshot
6.9.2 Company Overview
6.9.3 Financial Analysis
6.9.3.1 Net Revenue, 2017-2021
6.9.3.2 Operating Income, 2017-2021
6.9.3.3 Net Income, 2017-2021
6.9.3.4 EBITDA, 2017-2021
6.9.3.5 Company Regional Revenue Market Share
6.9.3.6 Company Business Segments Analysis
6.9.4 Service Benchmarking
6.9.5 Strategic Outlook
6.10 Abbott Laboratories
6.10.1 Company Snapshot
6.10.2 Company Overview
6.10.3 Financial Analysis
6.10.3.1 Net Revenue, 2017-2021
6.10.3.2 Operating Income, 2017-2021
6.10.3.3 Net Income, 2017-2021
6.10.3.4 EBITDA, 2017-2021
6.10.3.5 Company Regional Revenue Market Share
6.10.3.6 Company Business Segments Analysis
6.10.4 Service Benchmarking
6.10.5 Strategic Outlook
6.11 Thermo Fisher Scientific Inc.
6.11.1 Company Snapshot
6.11.2 Company Overview
6.11.3 Financial Analysis
6.11.3.1 Net Revenue, 2017-2021
6.11.3.2 Operating Income, 2017-2021
6.11.3.3 Net Income, 2017-2021
6.11.3.4 EBITDA, 2017-2021
6.11.3.5 Company Regional Revenue Market Share
6.11.3.6 Company Business Segment Analysis
6.11.4 Service Benchmarking
6.11.5 Strategic Outlook
6.12 AstraZeneca
6.12.1 Company Snapshot
6.12.2 Company Overview
6.12.3 Financial Analysis
6.12.3.1 Net Revenue, 2017-2021
6.12.3.2 Operating Income, 2017-2021
6.12.3.3 Net Income, 2017-2021
6.12.3.4 EBITDA, 2017-2021
6.12.3.5 Company Regional Revenue Market Share
6.12.3.6 Company Business Segments Analysis
6.12.4 Service Benchmarking
6.12.5 Strategic Outlook
6.13 Eli Lilly and Company
6.13.1 Company Snapshot
6.13.2 Company Overview
6.13.3 Financial Analysis
6.13.3.1 Net Revenue, 2017-2021
6.13.3.2 Operating Income, 2017-2021
6.13.3.3 Net Income, 2017-2021
6.13.3.4 EBITDA, 2017-2021
6.13.3.5 Company Regional Revenue Market Share
6.13.3.6 Company Business Segments Analysis
6.13.4 Service Benchmarking
6.13.5 Strategic Outlook
6.14 Gilead Sciences, Inc.
6.14.1 Company Snapshot
6.14.2 Company Overview
6.14.3 Financial Analysis
6.14.3.1 Net Revenue, 2017-2021
6.14.3.2 Operating Income, 2017-2021
6.14.3.3 Net Income, 2017-2021
6.14.3.4 EBITDA, 2017-2021
6.14.4 Service Benchmarking
6.14.5 Strategic Outlook
6.15 DuPont
6.15.1 Company Snapshot
6.15.2 Company Overview
6.15.3 Financial Analysis
6.15.3.1 Net Revenue, 2017-2021
6.15.3.2 Operating Income, 2017-2021
6.15.3.3 Net Income, 2017-2021
6.15.3.4 EBITDA, 2017-2021
6.15.4 Service Benchmarking
6.15.5 Strategic Outlook
6.16 Novo Nordisk A/S
6.16.1 Company Snapshot
6.16.2 Company Overview
6.16.3 Financial Analysis
6.16.3.1 Net Revenue, 2017-2021
6.16.3.2 Operating Income, 2017-2021
6.16.3.3 Net Income, 2017-2021
6.16.3.4 EBITDA, 2017-2021
6.16.3.5 Company Regional Revenue Market Share
6.16.3.6 Company Business Segments Analysis
6.16.4 Service Benchmarking
6.16.5 Strategic Outlook
6.17 Merck KGaA
6.17.1 Company Snapshot
6.17.2 Company Overview
6.17.3 Financial Analysis
6.17.3.1 Net Revenue, 2017-2021
6.17.3.2 Operating Income, 2017-2021
6.17.3.3 Net Income, 2017-2021
6.17.3.4 EBITDA, 2017-2021
6.17.4 Service Benchmarking
6.17.5 Strategic Outlook
6.18 BD
6.18.1 Company Snapshot
6.18.2 Company Overview
6.18.3 Financial Analysis
6.18.3.1 Net Revenue, 2017-2021
6.18.3.2 Operating Income, 2017-2021
6.18.3.3 Net Income, 2017-2021
6.18.3.4 EBITDA, 2017-2021
6.18.3.5 Company Regional Revenue Market Share
6.18.3.6 Company Business Segments Analysis
6.18.4 Service Benchmarking
6.18.5 Strategic Outlook
6.19 Teva Pharmaceuticals Industries Ltd.
6.19.1 Company Snapshot
6.19.2 Company Overview
6.19.3 Financial Analysis
6.19.3.1 Net Revenue, 2017-2021
6.19.3.2 Operating Income, 2017-2021
6.19.3.3 Net Income, 2017-2021
6.19.3.4 EBITDA, 2017-2021
6.19.4 Service Benchmarking
6.19.5 Strategic Outlook
6.20 Evonik Industries
6.20.1 Company Snapshot
6.20.2 Company Overview
6.20.3 Service Benchmarking
6.20.4 Strategic Outlook
6.21 UPM Pharmaceuticals
6.21.1 Company Snapshot
6.21.2 Company Overview
6.21.3 Service Benchmarking
6.21.4 Strategic Outlook
6.22 Baxter Biopharma Solutions
6.22.1 Company Snapshot
6.22.2 Company Overview
6.22.3 Financial Analysis
6.22.3.1 Net Revenue, 2017-2021
6.22.3.2 Operating Income, 2017-2021
6.22.3.3 Net Income, 2017-2021
6.22.3.4 EBITDA, 2017-2021
6.22.3.5 Company Regional Revenue Market Share
6.22.3.6 Company Business Segments Analysis
6.22.4 Service Benchmarking
6.22.5 Strategic Outlook
6.23 Boston Scientific Corporation
6.23.1 Company Snapshot
6.23.2 Company Overview
6.23.3 Financial Analysis
6.23.3.1 Net Revenue, 2017-2021
6.23.3.2 Operating Income, 2017-2021
6.23.3.3 Net Income, 2017-2021
6.23.3.4 EBITDA, 2017-2021
6.23.3.5 Company Regional Revenue Market Share
6.23.3.6 Company Business Segments Analysis
6.23.4 Service Benchmarking
6.23.5 Strategic Outlook
6.24 Koninklijke DSM N.V. (Royal DSM)
6.24.1 Company Snapshot
6.24.2 Company Overview
6.24.3 Financial Analysis
6.24.3.1 Net Revenue, 2017-2021
6.24.3.2 Operating Income, 2017-2021
6.24.3.3 Net Income, 2017-2021
6.24.3.4 EBITDA, 2017-2021
6.24.4 Service Benchmarking
6.24.5 Strategic Outlook
6.25 CSL Limited
6.25.1 Company Snapshot
6.25.2 Company Overview
6.25.3 Financial Analysis
6.25.3.1 Net Revenue, 2017-2021
6.25.3.2 Operating Income, 2017-2021
6.25.3.3 Net Income, 2017-2021
6.25.3.4 EBITDA, 2017-2021
6.25.3.5 Company Regional Revenue Market Share
6.25.3.6 Company Business Segments Analysis
6.25.4 Service Benchmarking
6.25.5 Strategic Outlook
6.26 Lonza
6.26.1 Company Snapshot
6.26.2 Company Overview
6.26.3 Financial Analysis
6.26.3.1 Net Revenue, 2017-2021
6.26.3.2 Operating Income, 2017-2021
6.26.3.3 Net Income, 2017-2021
6.26.3.4 EBITDA, 2017-2021
6.26.3.5 Company Regional Revenue Market Share
6.26.3.6 Company Business Segments Analysis
6.26.4 Service Benchmarking
6.26.5 Strategic Outlook
6.27 McKesson Corporation
6.27.1 Company Snapshot
6.27.2 Company Overview
6.27.3 Financial Analysis
6.27.3.1 Net Revenue, 2017-2021
6.27.3.2 Operating Income, 2017-2021
6.27.3.3 Net Income, 2017-2021
6.27.3.4 EBITDA, 2017-2021
6.27.3.5 Company Regional Revenue Market Share
6.27.3.6 Company Business Segments Analysis
6.27.4 Product Benchmarking
6.27.5 Strategic Outlook
6.28 Edwards Lifesciences Corporation
6.28.1 Company Snapshot
6.28.2 Company Overview
6.28.3 Financial Analysis
6.28.3.1 Net Revenue, 2017-2021
6.28.3.2 Operating Income, 2017-2021
6.28.3.3 Net Income, 2017-2021
6.28.3.4 EBITDA, 2017-2021
6.28.3.5 Company Regional Revenue Market Share
6.28.3.6 Company Business Segments Analysis
6.28.4 Product Benchmarking
6.28.5 Strategic Outlook
6.29 Nipro Corporation
6.29.1 Company Snapshot
6.29.2 Company Overview
6.29.3 Service Benchmarking
6.29.4 Strategic Outlook
6.30 PPD Inc.
6.30.1 Company Snapshot
6.30.2 Company Overview
6.30.3 Service Benchmarking
6.30.4 Strategic Outlook
6.31 Grifols
6.31.1 Company Snapshot
6.31.2 Company Overview
6.31.3 Financial Analysis
6.31.3.1 Net Revenue, 2017-2021
6.31.3.2 Operating Income, 2017-2021
6.31.3.3 Net Income, 2017-2021
6.31.3.4 EBITDA, 2017-2021
6.31.4 Service Benchmarking
6.31.5 Strategic Outlook
6.32 bioMérieux
6.32.1 Company Snapshot
6.32.2 Company Overview
6.32.3 Financial Analysis
6.32.3.1 Net Revenue, 2017-2021
6.32.3.2 Operating Income, 2017-2021
6.32.3.3 Net Income, 2017-2021
6.32.3.4 EBITDA, 2017-2021
6.32.3.5 Company Regional Revenue Market Share
6.32.3.6 Company Business Segments Analysis
6.32.4 Product Benchmarking
6.32.5 Strategic Outlook
6.33 Aurobindo Pharma
6.33.1 Company Snapshot
6.33.2 Company Overview
6.33.3 Service Benchmarking
6.33.4 Strategic Outlook
6.34 Dr. Reddy's Laboratories Ltd.
6.34.1 Company Snapshot
6.34.2 Company Overview
6.34.3 Financial Analysis
6.34.3.1 Net Revenue, 2017-2021
6.34.3.2 Operating Income, 2017-2021
6.34.3.3 Net Income, 2017-2021
6.34.3.4 EBITDA, 2017-2021
6.34.3.5 Company Regional Revenue Market Share
6.34.3.6 Company Business Segments Analysis
6.34.4 Service Benchmarking
6.34.5 Strategic Outlook
6.35 WuXi AppTec
6.35.1 Company Snapshot
6.35.2 Company Overview
6.35.3 Service Benchmarking
6.35.4 Strategic Outlook
6.36 Huapont Life Sciences Co Ltd.
6.36.1 Company Snapshot
6.36.2 Company Overview
6.36.3 Service Benchmarking
6.37 ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.
6.37.1 Company Snapshot
6.37.2 Company Overview
6.37.3 Service Benchmarking
6.37.4 Strategic Outlook
6.38 Alkermes
6.38.1 Company Snapshot
6.38.2 Company Overview
6.38.3 Financial Analysis
6.38.3.1 Net Revenue, 2017-2021
6.38.3.2 Operating Income, 2017-2021
6.38.3.3 Net Income, 2017-2021
6.38.3.4 EBITDA, 2017-2021
6.38.4 Service Benchmarking
6.38.5 Strategic Outlook
6.39 Emergent BioSolutions
6.39.1 Company Snapshot
6.39.2 Company Overview
6.39.3 Financial Analysis
6.39.3.1 Net Revenue, 2017-2021
6.39.3.2 Operating Income, 2017-2021
6.39.3.3 Net Income, 2017-2021
6.39.3.4 EBITDA, 2017-2021
6.39.4 Service Benchmarking
6.39.5 Strategic Outlook
6.40 Divi's Laboratories Limited
6.40.1 Company Snapshot
6.40.2 Company Overview
6.40.3 Service Benchmarking
6.41 Bavarian Nordic
6.41.1 Company Snapshot
6.41.2 Company Overview
6.41.3 Financial Analysis
6.41.3.1 Net Revenue, 2017-2021
6.41.3.2 Operating Income, 2017-2021
6.41.3.3 Net Income, 2017-2021
6.41.3.4 EBITDA, 2017-2021
6.41.3.5 Company Regional Revenue Market Share
6.41.3.6 Company Business Segments Analysis
6.41.4 Service Benchmarking
6.41.5 Strategic Outlook
6.42 Strides Pharma Science Limited
6.42.1 Company Snapshot
6.42.2 Company Overview
6.42.3 Service Benchmarking
6.42.4 Strategic Outlook
6.43 Consort Medical plc
6.43.1 Company Snapshot
6.43.2 Company Overview
6.43.3 Service Benchmarking
6.43.4 Strategic Outlook
6.44 Catalent Inc.
6.44.1 Company Snapshot
6.44.2 Company Overview
6.44.3 Financial Analysis
6.44.3.1 Net Revenue, 2017-2021
6.44.3.2 Operating Income, 2017-2021
6.44.3.3 Net Income, 2017-2021
6.44.3.4 EBITDA, 2017-2021
6.44.3.5 Company Regional Revenue Market Share
6.44.3.6 Company Business Segments Analysis
6.44.4 Service Benchmarking
6.44.5 Strategic Outlook
6.45 Moderna Inc.
6.45.1 Company Snapshot
6.45.2 Company Overview
6.45.3 Financial Analysis
6.45.3.1 Net Revenue, 2017-2021
6.45.3.2 Operating Income, 2017-2021
6.45.3.3 Net Income, 2017-2021
6.45.3.4 EBITDA, 2017-2021
6.45.4 Service Benchmarking
6.45.5 Strategic Outlook
6.46 Avid Bioservices, Inc.
6.46.1 Company Snapshot
6.46.2 Company Overview
6.46.3 Financial Analysis
6.46.3.1 Net Revenue, 2017-2021
6.46.3.2 Operating Income, 2017-2021
6.46.3.3 Net Income, 2017-2021
6.46.3.4 EBITDA, 2017-2021
6.46.4 Service Benchmarking
6.46.5 Strategic Outlook
6.47 Novavax
6.47.1 Company Snapshot
6.47.2 Company Overview
6.47.3 Financial Analysis
6.47.3.1 Net Revenue, 2017-2021
6.47.3.2 Operating Income, 2017-2021
6.47.3.3 Net Income, 2017-2021
6.47.3.4 EBITDA, 2017-2021
6.47.4 Service Benchmarking
6.47.5 Strategic Outlook
6.48 INOVIO Pharmaceuticals
6.48.1 Company Snapshot
6.48.2 Company Overview
6.48.3 Financial Analysis
6.48.3.1 Net Revenue, 2017-2021
6.48.3.2 Operating Income, 2017-2021
6.48.3.3 Net Income, 2017-2021
6.48.3.4 EBITDA, 2017-2021
6.48.4 Service Benchmarking
6.48.5 Strategic Outlook
6.49 VBI Vaccines Inc.
6.49.1 Company Snapshot
6.49.2 Company Overview
6.49.3 Financial Analysis
6.49.3.1 Net Revenue, 2017-2021
6.49.3.2 Operating Income, 2017-2021
6.49.3.3 Net Income, 2017-2021
6.49.3.4 EBITDA, 2017-2021
6.49.4 Service Benchmarking
6.49.5 Strategic Outlook
6.50 Fresenius SE&Co. KGaA
6.50.1 Company Snapshot
6.50.2 Company Overview
6.50.3 Financial Analysis
6.50.3.1 Net Revenue, 2017-2021
6.50.3.2 Operating Income, 2017-2021
6.50.3.3 Net Income, 2017-2021
6.50.3.4 EBITDA, 2017-2021
6.50.3.5 Company Regional Revenue Market Share
6.50.3.6 Company Business Segments Analysis
6.50.4 Service Benchmarking
6.50.5 Strategic Outlook
7 Conclusion and Recommendations
7.1 Concluding Remarks from Visiongain
7.2 Recommendations for Market Players
7.2.4 Biopharma Manufacturing Demand Will Drive Growth 2022-2032
List of Tables
Table 1 Pharmaceutical Contract Manufacturing Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (USD Bn, AGR (%), CAGR (%)) (V-Shaped Recovery Scenario)
Table 3 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022 2032 (USD Bn, AGR (%), CAGR (%)) (U-Shaped Recovery Scenario)
Table 4 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (USD Bn, AGR (%), CAGR (%)) (W-Shaped Recovery Scenario)
Table 5 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (USD Bn, AGR (%), CAGR (%)) (L-Shaped Recovery Scenario)
Table 6 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%))
Table 7 Market Share of Contract Manufacturing Companies Providing Bulk Drugs and APIs, 2021 (%)
Table 8 Market Share of Contract Manufacturing Companies Providing Solid Dosage Forms, 2021, (%)
Table 9 Market Share of Contract Manufacturing Companies Providing Nonsterile Liquid Dosage Forms, 2021 (%)
Table 10 Market Share of Contract Manufacturing Companies Providing Sterile Liquid Dosage Forms, 2021
Table 11 Market Share of Contract Manufacturing Companies Providing Sterile Liquid Dosage Forms, 2021
Table 12 Johnson & Johnson Services Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 13 Johnson & Johnson Services Inc.: Service Benchmarking
Table 14 Johnson & Johnson Services Inc.: Strategic Outlook
Table 15 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 16 F. Hoffmann-La Roche Ltd: Service Benchmarking
Table 17 F. Hoffmann-La Roche Ltd: Strategic Outlook
Table 18 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 19 Pfizer Inc.: Service Benchmarking
Table 20 Pfizer Inc.: Strategic Outlook
Table 21 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 22 Bayer AG: Service Benchmarking
Table 23 Bayer AG: Strategic Outlook
Table 24 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 25 Novartis AG: Service Benchmarking
Table 26 Novartis AG: Strategic Outlook
Table 27 CordenPharma International: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 28 CordenPharma International: Service Benchmarking
Table 29 CordenPharma International: Strategic Outlook
Table 30 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 31 GSK plc: Service Benchmarking
Table 32 GSK plc: Strategic Outlook
Table 33 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 34 Sanofi: Service Benchmarking
Table 35 Sanofi: Strategic Outlook
Table 36 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 37 AbbVie Inc.: Service Benchmarking
Table 38 AbbVie Inc.: Strategic Outlook
Table 39 Abbott Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 40 Abbott Laboratories: Service Benchmarking
Table 41 Abbott Laboratories: Strategic Outlook
Table 42 Thermo Fisher Scientific Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 43 Thermo Fisher Scientific Inc.: Service Benchmarking
Table 44 Thermo Fisher Scientific Inc.: Strategic Outlook
Table 45 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 46 AstraZeneca: Service Benchmarking
Table 47 AstraZeneca: Strategic Outlook
Table 48 Eli Lily and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 49 Eli Lily and Company: Service Benchmarking
Table 50 Eli Lily and Company: Strategic Outlook
Table 51 Gilead Science Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 52 Gilead Science Inc.: Service Benchmarking
Table 53 Gilead Science Inc.: Strategic Outlook
Table 54 DuPont: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 55 DuPont: Service Benchmarking
Table 56 DuPont: Strategic Outlook
Table 57 Novo Nordisk A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 58 Novo Nordisk A/S: Service Benchmarking
Table 59 Novo Nordisk A/S: Strategic Outlook
Table 60 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 61 Merck KGaA: Service Benchmarking
Table 62 Merck KGaA: Strategic Outlook
Table 63 BD: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 64 BD: Service Benchmarking
Table 65 BD: Strategic Outlook
Table 66 Teva Pharmaceutical: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 67 Teva Pharmaceutical: Service Benchmarking
Table 68 Teva Pharmaceutical: Strategic Outlook
Table 69 Evonik Industries: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 Evonik Industries: Service Benchmarking
Table 71 Evonik Industries: Strategic Outlook
Table 72 UPM Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 UPM Pharmaceuticals: Service Benchmarking
Table 74 UPM Pharmaceuticals: Strategic Outlook
Table 75 Baxter Biopharma Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 76 Baxter Biopharma Solutions: Service Benchmarking
Table 77 Baxter Biopharma Solutions: Strategic Outlook
Table 78 Boston Scientific Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Boston Scientific Corporation: Service Benchmarking
Table 80 Boston Scientific Corporation: Strategic Outlook
Table 81 Koninklijke DSM N.V: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Koninklijke DSM N.V: Service Benchmarking
Table 83 Koninklijke DSM N.V: Strategic Outlook
Table 84 CSL Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 CSL Limited: Service Benchmarking
Table 86 CSL Limited: Strategic Outlook
Table 87 Lonza: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Lonza: Service Benchmarking
Table 89 Lonza: Strategic Outlook
Table 90 McKesson Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 McKesson Corporation: Service Benchmarking
Table 92 McKesson Corporation: Strategic Outlook
Table 93 Edwards Lifesciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Edwards Lifesciences: Service Benchmarking
Table 95 Edwards Lifesciences: Strategic Outlook
Table 96 Nipro Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Nipro Corporation: Service Benchmarking
Table 98 Nipro Corporation: Strategic Outlook
Table 99 PPD Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 PPD Inc.: Service Benchmarking
Table 101 PPD Inc.: Strategic Outlook
Table 102 Grifols: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Grifols: Service Benchmarking
Table 104 Grifols: Strategic Outlook
Table 105 bioMérieux: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Table 110 bioMérieux: Service Benchmarking
Table 107 bioMérieux: Strategic Outlook
Table 108 Aurobindo Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 Aurobindo Pharma: Service Benchmarking
Table 110 Aurobindo Pharma: Strategic Outlook
Table 111 Dr. Reddy's Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 112 Dr. Reddy's Laboratories Ltd.: Service Benchmarking
Table 113 Dr. Reddy's Laboratories Ltd.: Strategic Outlook
Table 114 Wuxi AppTec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Wuxi AppTec: Service Benchmarking
Table 116 Wuxi AppTec: Strategic Outlook
Table 117 Huapont Life Sciences Co Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Huapont Life Sciences Co Ltd: Service Benchmarking
Table 119 ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 120 ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.: Service Benchmarking
Table 121 ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.: Strategic Outlook
Table 122 Alkermes: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Alkermes: Service Benchmarking
Table 124 Alkermes: Strategic Outlook
Table 125 Emergent BioSolutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Emergent BioSolutions: Service Benchmarking
Table 127 Emergent BioSolutions: Strategic Outlook
Table 128 Divi’s Laboratories Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 129 Divi’s Laboratories Limited: Service Benchmarking
Table 130 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Bavarian Nordic: Service Benchmarking
Table 132 Bavarian Nordic K: Strategic Outlook
Table 133 Strides Pharma Science Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 134 Strides Pharma Science Ltd: Service Benchmarking
Table 135 Strides Pharma Science Limited: Strategic Outlook
Table 136 Consort Medical plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 137 Consort Medical plc: Service Benchmarking
Table 138 Consort Medical plc: Strategic Outlook
Table 139 Catalent Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 140 Catalent Inc: Service Benchmarking
Table 141 Catalent Pharma Solutions Inc: Strategic Outlook
Table 142 Moderna Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 143 Moderna Inc.: Service Benchmarking
Table 144 Moderna Inc.: Strategic Outlook
Table 145 Avid Bioservices, Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 146 Avid Bioservices, Inc: Service Benchmarking
Table 147 Avid Bioservices, Inc: Strategic Outlook
Table 148 Novavax: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 149 Novavax: Service Benchmarking
Table 150 Novavax: Strategic Outlook
Table 151 INOVIO Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 152 INOVIO Pharmaceuticals: Service Benchmarking
Table 153 INOVIO Pharmaceuticals: Strategic Outlook
Table 154 VBI Vaccines Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 155 VBI Vaccines Biotechnology: Service Benchmarking
Table 156 VBI Vaccines Biotechnology: Strategic Outlook
Table 157 Fresenius SE&Co. KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 158 Fresenius SE&Co. KGaA: Service Benchmarking
Table 159 Fresenius SE&Co. KGaA: Strategic Outlook
List of Figures
Figure 1 Pharmaceutical Contract Manufacturing Organisations (CMO): Market Dynamics
Figure 2 COVID Impact Analysis: Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Recovery Scenarios
Figure 3 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%)): “V” Shaped Recovery
Figure 4 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%)): “U” Shaped Recovery
Figure 5 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%)): “W” Shaped Recovery
Figure 6 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%)): “L” Shaped Recovery
Figure 7 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market: Porter’s Five Forces Analysis
Figure 8 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Forecast by Region 2022, 2027, 2032 (Revenue, CAGR%)
Figure 9 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market by Region, 2022-2032 (US$ mn, AGR (%))
Figure 10 Johnson & Johnson Services Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 11 Johnson & Johnson Services Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 12 Johnson & Johnson Services Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 13 Johnson & Johnson Services Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 14 Johnson & Johnson Services Inc.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 15 Johnson & Johnson Services Inc.: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 16 F. Hoffmann-La Roche Ltd: Revenue, 2017-2021 (US$ million, AGR%)
Figure 17 F. Hoffmann-La Roche Ltd: Operating Income 2017-2021 (US$ million, AGR%)
Figure 18 F. Hoffmann-La Roche Ltd: Net Income 2017-2021 (US$ million, AGR%)
Figure 19 F. Hoffmann-La Roche Ltd: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 20 F. Hoffmann-La Roche Ltd: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 21 F. Hoffmann-La Roche Ltd: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Source: Visiongain Reports Ltd., 2022
Figure 22 Pfizer Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 23 Pfizer Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 24 Pfizer Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 25 Pfizer Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 26 Pfizer Inc.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 27 Bayer AG: Revenue, 2017-2021 (US$ million, AGR%)
Figure 28 Bayer AG: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 29 Bayer AG: Net Income 2017-2021 (US$ million, AGR%)
Figure 30 Bayer AG: EBITDA, 2017-2021 (US$million)
Figure 31 Bayer AG: Company Regional Revenue Market Share Analysis 2021(%)
Figure 32 Bayer AG: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 33 Novartis AG: Revenue, 2017-2021 (US$ million, AGR%)
Figure 34 Novartis AG: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 35 Novartis AG: Net Income 2017-2021 (US$ million, AGR%)
Figure 36 Novartis AG: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 37 Novartis AG: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 38 Novartis AG: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 39 GSK plc: Revenue, 2017-2021 (US$ million, AGR%)
Figure 40 GSK plc: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 41 GSK plc: Net Income 2017-2021 (US$ million, AGR%)
Figure 42 GSK plc: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 43 GSK plc: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 44 GSK plc: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 45 Sanofi: Revenue, 2017-2021 (US$ million, AGR%)
Figure 46 Sanofi: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 47 Sanofi: Net Income 2017-2021 (US$ million, AGR%)
Figure 48 Sanofi: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 49 Sanofi: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 50 Sanofi: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 51 AbbVie Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 52 AbbVie Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 53 AbbVie Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 54 AbbVie Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 55 AbbVie Inc.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 56 AbbVie Inc.: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 57 Abbott Laboratories: Revenue, 2017-2021 (US$ million, AGR%)
Figure 58 Abbott Laboratories: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 59 Abbott Laboratories: Net Income 2017-2021 (US$ million, AGR%)
Figure 60 Abbott Laboratories: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 61 Abbott Laboratories: Company Regional Revenue Market Share Analysis 2021(%)
Figure 62 Abbott Laboratories: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 63 Thermo Fisher Scientific Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 64 Thermo Fisher Scientific Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 65 Thermo Fisher Scientific Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 66 Thermo Fisher Scientific Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 67 Thermo Fisher Scientific Inc.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 68 Thermo Fisher Scientific Inc.: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 69 AstraZeneca: Revenue, 2017-2021 (US$ million, AGR%)
Figure 70 AstraZeneca: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 71 AstraZeneca: Net Income 2017-2021 (US$ million, AGR%)
Figure 72 AstraZeneca: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 73 AstraZeneca: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 74 AstraZeneca: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 75 Eli Lily and Company: Revenue, 2017-2021 (US$ million, AGR%)
Figure 76 Eli Lily and Company: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 77 Eli Lily and Company: Net Income 2017-2021 (US$ million, AGR%)
Figure 78 Eli Lily and Company: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 79 Eli Lily and Company: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 80 Eli Lily and Company: Company Revenue Breakdown by Business Segments Analysis 2021(%)
Figure 81 Gilead Science Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 82 Gilead Science Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 83 Gilead Science Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 84 Gilead Science Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 85 DuPont: Revenue, 2017-2021 (US$ million, AGR%)
Figure 86 DuPont: Operating Income, 2017-2021 (US$ million)
Figure 87 DuPont: Net Income 2017-2021 (US$ million)
Figure 88 DuPont: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 89 Novo Nordisk A/S: Revenue, 2017-2021 (US$ million, AGR%)
Figure 90 Novo Nordisk A/S: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 91 Novo Nordisk A/S: Net Income 2017-2021 (US$ million, AGR%)
Figure 92 Novo Nordisk A/S: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 93 Novo Nordisk A/S: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 94 Novo Nordisk A/S: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 95 Merck KGaA: Revenue, 2017-2021 (US$ million, AGR%)
Figure 96 Merck KGaA: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 97 Merck KGaA: Net Income 2017-2021 (US$ million, AGR%)
Figure 98 Merck KGaA: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 99 Merck KGaA: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 100 Merck KGaA: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 101 BD: Revenue, 2017-2021 (US$ million, AGR%)
Figure 102 BD: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 103 BD: Net Income 2017-2021 (US$ million, AGR%)
Figure 104 BD: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 105 BD: Regional Revenue Market Share Analysis 2021 (%)
Figure 106 BD: Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 107 Teva Pharmaceutical: Revenue, 2017-2021 (US$ million, AGR%)
Figure 108 Teva Pharmaceutical: Operating Income, 2017-2021 (US$ million)
Figure 109 Teva Pharmaceutical: Net Income 2017-2021 (US$ million)
Figure 110 Teva Pharmaceutical: EBITDA, 2017-2021 (US$ million)
Figure 111 Baxter Biopharma Solutions: Revenue, 2017-2021 (US$ million, AGR%)
Figure 112 Baxter Biopharma Solutions: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 113 Baxter Biopharma Solutions: Net Income 2017-2021 (US$ million, AGR%)
Figure 114 Baxter Biopharma Solutions: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 115 Baxter Biopharma Solutions: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 116 Baxter Biopharma Solutions: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 117 Boston Scientific Corporation: Revenue, 2017-2021 (US$ million, AGR%)
Figure 118 Boston Scientific Corporation: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 119 Boston Scientific Corporation: Net Income 2017-2021 (US$ million)
Figure 120 Boston Scientific Corporation: EBITDA, 2017-2021 (US$ million)
Figure 121 Boston Scientific Corporation: Company Regional Revenue Market Share Analysis 2021(US$Mn)
Figure 122 Boston Scientific Corporation: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 123 Koninklijke DSM N.V: Revenue, 2017-2021 (US$ million, AGR%)
Figure 124 Koninklijke DSM N.V: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 125 Koninklijke DSM N.V: Net Income 2017-2021 (US$ million, AGR%)
Figure 126 Koninklijke DSM N.V: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 127 CSL Limited: Revenue, 2017-2021 (US$ million, AGR%)
Figure 128 CSL Limited: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 129 CSL Limited: Net Income 2017-2021 (US$ million, AGR%)
Figure 130 CSL Limited: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 131 CSL Limited: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 132 CSL Limited: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 133 Lonza: Revenue, 2017-2021 (US$ million, AGR%)
Figure 134 Lonza: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 135 Lonza: Net Income 2017-2021 (US$ million, AGR%)
Figure 136 Lonza: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 137 Lonza: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 138 Lonza Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 139 McKesson Corporation: Revenue, 2017-2021 (US$ million, AGR%)
Figure 140 McKesson Corporation: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 141 McKesson Corporation: Net Income 2017-2021 (US$ million, AGR%)
Figure 142 McKesson Corporation: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 143 McKesson Corporation: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 144 McKesson Corporation: Company Revenue Breakdown by Business Segments Analysis 2021 (%)
Figure 145 Edwards Lifesciences: Revenue, 2017-2021 (US$ million, AGR%)
Figure 146 Edwards Lifesciences: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 147 Edwards Lifesciences: Net Income 2017-2021 (US$ million, AGR%)
Figure 148 Edwards Lifesciences: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 149 Edwards Lifesciences: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 150 Edwards Lifesciences: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 151 Grifols: Revenue, 2017-2021 (US$ million, AGR%)
Figure 152 Grifols: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 153 Grifols: Net Income 2017-2021 (US$ million, AGR%)
Figure 154 Grifols: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 155 bioMérieux: Revenue, 2017-2021 (US$ million, AGR%)
Figure 156 bioMérieux: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 157 bioMérieux: Net Income 2017-2021 (US$ million, AGR%)
Figure 158 bioMérieux: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 159 bioMérieux: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 160 bioMérieux: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 161 Dr. Reddy's Laboratories Ltd.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 162 Dr. Reddy's Laboratories Ltd.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 163 Dr. Reddy's Laboratories Ltd.: Net Income 2017-2021 (US$ million, AGR%)
Figure 164 Dr. Reddy's Laboratories Ltd.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 165 Dr. Reddy's Laboratories Ltd.: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 166 Dr. Reddy's Laboratories Ltd. Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 167 Alkermes: Revenue, 2017-2021 (US$ million, AGR%)
Figure 168 Alkermes: Operating Income, 2017-2021 (US$ million)
Figure 169 Alkermes: Net Income 2017-2021 (US$ million)
Figure 170 Alkermes: EBITDA, 2017-2021 (US$ million)
Figure 171 Emergent BioSolutions: Revenue, 2017-2021 (US$ million, AGR%)
Figure 172 Emergent BioSolutions: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 173 Emergent BioSolutions: Net Income 2017-2021 (US$ million, AGR%)
Figure 174 Emergent BioSolutions: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 175 Bavarian Nordic: Revenue, 2017-2021 (US$ million, AGR%)
Figure 176 Bavarian Nordic: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 177 Bavarian Nordic: Net Income 2017-2021 (US$ million, AGR%)
Figure 178 Bavarian Nordic: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 179 Bavarian Nordic: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 180 Bavarian Nordic: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 181 Catalent Inc: Revenue, 2017-2021 (US$ million, AGR%)
Figure 182 Catalent Inc: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 183 Catalent Inc: Net Income 2017-2021 (US$ million, AGR%)
Figure 184 Catalent Inc: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 185 Catalent Inc: Company Regional Revenue Market Share Analysis 2021 (%)
Figure 186 Catalent Inc: Company Revenue Breakdown by Business Segments Analysis, 2021 (%)
Figure 187 Moderna Inc.: Revenue, 2017-2021 (US$ million, AGR%)
Figure 188 Moderna Inc.: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 189 Moderna Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 190 Moderna Inc.: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 191 Avid Bioservices, Inc: Revenue, 2017-2021 (US$ million, AGR%)
Figure 192 Avid Bioservices, Inc: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 193 Avid Bioservices, Inc: Net Income 2017-2021 (US$ million, AGR%)
Figure 194 Avid Bioservices, Inc: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 195 Novavax: Revenue, 2017-2021 (US$ million, AGR%)
Figure 196 Novavax Operating Income, 2017-2021 (US$ million)
Figure 197 Novavax: Net Income 2017-2021 (US$ million)
Figure 198 Novavax: EBITDA, 2017-2021 (US$ million)
Figure 199 INOVIO Pharmaceuticals: Revenue, 2017-2021 (US$ million, AGR%)
Figure 200 INOVIO Pharmaceuticals: Operating Income, 2017-2021 (US$ million)
Figure 201 INOVIO Pharmaceuticals: Net Income 2017-2021 (US$ million)
Figure 202 INOVIO Pharmaceuticals: EBITDA, 2017-2021 (US$ million)
Figure 203 VBI Vaccines Inc.: Revenue, 2017-2021 (US$ million)
Figure 204 VBI Vaccines Inc.: Operating Income, 2017-2021 (US$ million)
Figure 205 VBI Vaccines Inc.: Net Income 2017-2021 (US$ million, AGR%)
Figure 206 VBI Vaccines Inc.: EBITDA, 2017-2021 (US$ million)
Figure 207 Fresenius SE&Co. KGaA: Revenue, 2017-2021 (US$ million, AGR%)
Figure 208 Fresenius SE&Co. KGaA: Operating Income, 2017-2021 (US$ million, AGR%)
Figure 209 Fresenius SE&Co. KGaA: Net Income 2017-2021 (US$ million, AGR%)
Figure 210 Fresenius SE&Co. KGaA: EBITDA, 2017-2021 (US$ million, AGR%)
Figure 211 Fresenius SE&Co. KGaA: Regional Market Share 2021 (%)
Figure 212 Fresenius SE&Co. KGaA: Business Segment Share (%), 2021
ページTOPに戻る
本レポートと同分野（その他（治療を主目的としない薬物））の最新刊レポート
本レポートと同じKEY WORD（contract manufacturing）の最新刊レポート
よくあるご質問
Visiongain社はどのような調査会社ですか?
英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る
調査レポートの納品までの日数はどの程度ですか?
在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。
注文の手続きはどのようになっていますか?
1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。
お支払方法の方法はどのようになっていますか?
納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。
データリソース社はどのような会社ですか?
当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。
|
|
